Value
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Fwd P/E | 1.5 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 68.0x
- ▸PEG: 0.37
BLTE · Why this verdict
Why Belite Bio (BLTE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Belite Bio is a pre-revenue biotech with strong price momentum, light but positive analyst coverage and 27.9% upside to the analyst target, but widening losses, repeated earnings misses, no moat and heavy insider selling make it a speculative holding.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality scores only 1.6 with return on equity, margins and gross margin all at 0.0, no competitive moat and a Piotroski F-Score of just 4.4. Quality breakdown | The company advances its pipeline so that quality rises above 3.0 over 12 months. | →Stable |
| CounterFor a clinical-stage biotech, zero margins are expected, and the value lies in pipeline outcomes that the quality score cannot capture. | ||
The company missed estimates in 3 of the last 4 quarters with an average surprise of -14.7%, including -30.3% on 2026-03-02 and -32.7% on 2025-11-10, and loss per share is about -0.70. Last 4 quarters | Quarterly loss per share narrows to better than -0.60 over the next four quarters. | →Stable |
| CounterThe most recent quarter was a +9.9% beat (-0.70 versus -0.78 expected), suggesting the miss trend may be turning. | ||
Momentum is 7.3/10 with rising on-balance volume and a MACD score of 10, and price is in a pullback below a still-rising 200-day average. Momentum breakdown | Price holds above the $143.91 stop level and momentum stays at or above 6.0 through the next quarter. | ↑Improving |
| CounterPrice is still below its 200-day average and RSI of 46 shows a range-bound market rather than a confirmed uptrend. | ||
Price of $154.74 is 27.9% below the analyst target of $197.88, with analyst-implied upside of 47% before the haircut, but coverage is light. Sentiment breakdown | Price moves toward the $197.88 target as clinical milestones are reached over 12 months. | →Stable |
| CounterLight analyst coverage (9.0) dampens the signal, and biotech targets depend on binary trial outcomes. | ||
Insiders sold about $32.1 million, equal to 0.515% of market cap and rated heavy, even as institutions are accumulating. Insider breakdown | Insider selling slows below 0.2% of market cap over the next two quarters. | →Stable |
| CounterSelling by founders or early holders in a biotech can be liquidity-driven, and institutional accumulation offsets the signal. | ||
Quality scores only 1.6 with return on equity, margins and gross margin all at 0.0, no competitive moat and a Piotroski F-Score of just 4.4.
→StableQuality breakdown
- Expectation
- The company advances its pipeline so that quality rises above 3.0 over 12 months.
CounterFor a clinical-stage biotech, zero margins are expected, and the value lies in pipeline outcomes that the quality score cannot capture.
The company missed estimates in 3 of the last 4 quarters with an average surprise of -14.7%, including -30.3% on 2026-03-02 and -32.7% on 2025-11-10, and loss per share is about -0.70.
→StableLast 4 quarters
- Expectation
- Quarterly loss per share narrows to better than -0.60 over the next four quarters.
CounterThe most recent quarter was a +9.9% beat (-0.70 versus -0.78 expected), suggesting the miss trend may be turning.
Momentum is 7.3/10 with rising on-balance volume and a MACD score of 10, and price is in a pullback below a still-rising 200-day average.
↑ImprovingMomentum breakdown
- Expectation
- Price holds above the $143.91 stop level and momentum stays at or above 6.0 through the next quarter.
CounterPrice is still below its 200-day average and RSI of 46 shows a range-bound market rather than a confirmed uptrend.
Price of $154.74 is 27.9% below the analyst target of $197.88, with analyst-implied upside of 47% before the haircut, but coverage is light.
→StableSentiment breakdown
- Expectation
- Price moves toward the $197.88 target as clinical milestones are reached over 12 months.
CounterLight analyst coverage (9.0) dampens the signal, and biotech targets depend on binary trial outcomes.
Insiders sold about $32.1 million, equal to 0.515% of market cap and rated heavy, even as institutions are accumulating.
→StableInsider breakdown
- Expectation
- Insider selling slows below 0.2% of market cap over the next two quarters.
CounterSelling by founders or early holders in a biotech can be liquidity-driven, and institutional accumulation offsets the signal.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 3.8 |
| Piotroski F | 4.4 |
- ▸No competitive moat
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| EPS growth | 10.0 |
Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 1.7 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+0.1%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.0 |
| Price target | 9.5 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 48%
Insider
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $32,100,749 (0.519% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 6.0 |
| growth rank | 5.0 |
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.3 |
| support resistance | 3.5 |
| 52w position | 5.4 |
Risk (lower is worse)
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.0 |
| days to cover | 2.5 |
| volatility | 2.6 |
| put call | 9.3 |
| implied vol | 1.4 |
- ▸High IV: 72%
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/3M
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:6.3>=5.5
- ASYMMETRY:3.5>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- INSIDER:0.52%=HEAVY
- EARNINGS_PROXIMITY:6d<=7d
Warning (0)
none
Reward-to-Risk
3.49
Upside
+28.4%
Downside
8.1%
Sizing output
AVOID
SetupRange Bound — RSI 52 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the INSIDER gate's 0.52%=HEAVY outcome against Growth at 10.0 and asymmetric R:R of 3.49.
The strongest dimensions are Growth at 10.0, Sentiment at 7.7, and Value at 6.8; the weakest are Quality at 1.6, Catalyst at 2.5, and Technical at 4.1. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 3.49 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Pre Revenue Quality Weakness
Trip ifQuality score falls below 1.0 from current 1.6.
- P2Repeated Earnings Misses
Trip ifQuarterly loss per share widens beyond -0.80 from current -0.70.
- P3Strong Momentum With Accumulation
Trip ifMomentum score falls below 5.0 from current 7.3.
- P4Analyst Upside Light Coverage
Trip ifPrice drops to $143.91 or below, the stop level, before the analyst target is reached.
- P5Heavy Insider Selling
Trip ifInsider selling exceeds 1.0% of market cap over a 90-day window from current 0.515%.